Currently, there is a significant trend in the pharmaceutical industry to produce what is called “chiral switches”: chiral drugs already commercialised as racemates that could be developed as a single enantiomer [ 4 ].
← all excerpts
Towards EMIC rational design: setting the molecular simulation toolbox for enantiopure molecularly imprinted catalysts.
1
—
—